Wexler Boley & Elgersma LLP, Others Appointed Interim Co-Lead Class Counsel in Copaxone Antitrust Litigation

On Thursday, August 11, 2022, United States Magistrate Judge Jessica S. Allen signed an order appointing WBE attorneys Kenneth A. Wexler and Justin N. Boley as interim co-lead counsel in the case In re Copaxone Antitrust Litigation, case number 2:22-cv-01232, pending in the United States District Court for the District of New Jersey. Additional interim co-leads are Sharon K. Robertson of Cohen Milstein Sellers & Toll PLLC and Archana Tamoshunas of Taus, Cebulash & Landau LLP.  Christopher Seeger and Jennifer Scullion of Seeger Weiss will act as liaison counsel for the proposed third-party payor class.

WBE and co-counsel brought this antitrust lawsuit against drugmaker Teva Pharmaceuticals in early 2022. The lawsuit alleges that Teva illegally suppressed generic competition for its blockbuster multiple sclerosis drug Copaxone by entering into exclusionary contracts and spreading misinformation about generic competitors. As alleged in the complaint, this conduct forced plaintiffs and the putative class to pay more for their medication than they should have.

To read a copy of the court’s order appointing interim co-lead and liaison counsel, click here.